Literature DB >> 36176570

Impact of a Pharmacist-Managed Procalcitonin Program on COVID-19 Respiratory Tract Infection Outcomes and Health Care Resource Utilization.

Andrew J Fratoni1, Abigail K Kois1, Jessica L Colmerauer2, Kristin E Linder2, David P Nicolau1, Joseph L Kuti1.   

Abstract

Patients hospitalized with coronavirus disease 2019 (COVID-19) often receive empiric antibiotic coverage. Procalcitonin (PCT) is a biomarker with Food and Drug Administration-approved guidance cutoffs for antibiotic use in lower respiratory tract infections. Herein we describe the implementation and impact of a pharmacist-managed PCT monitoring program in hospitalized patients with COVID-19. In this quasi-experimental, single-center, retrospective study of a prospective antimicrobial stewardship pharmacist-managed program, inpatients who were severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction positive were reviewed during weekday working hours and evaluated for appropriateness of antibiotic treatment by utilizing the PCT biomarker. As needed, the infectious diseases pharmacist offered feedback around antibiotic discontinuation in patients with PCT values ≤0.25 ng/mL. Adherence to PCT cutoffs, clinical outcomes, and utilization of health care resources were quantified and compared with a time frame immediately preceding the program's implementation. A total of 772 patients hospitalized with COVID-19 were analyzed. The pre-intervention cohort was comprised of 519 patients, and 253 patients were included after program implementation. Antibiotics were prescribed within 72 hours of admission to 232 (44.7%) and 108 (42.7%) patients during the control and intervention phases, respectively. There was no difference in the primary outcome of percentage of patients who received >1 day of antibiotic therapy (23.5% vs 21.7%; P = .849) or in any secondary outcome including hospital length of stay, 30-day readmission rates, or discharge disposition. In a hospital where the majority of COVID-19 patients did not receive empiric antibiotics, the implementation of a pharmacist-managed PCT monitoring program did not significantly decrease antibiotic use or health care resource utilization.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Entities:  

Keywords:  antimicrobial stewardship; biomarker; coronavirus; pneumonia

Year:  2022        PMID: 36176570      PMCID: PMC9494375          DOI: 10.1093/ofid/ofac468

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   4.423


  18 in total

1.  Procalcitonin in early detection of postoperative complications.

Authors:  H B Reith; U Mittelkötter; E S Debus; C Küssner; A Thiede
Journal:  Dig Surg       Date:  1998       Impact factor: 2.588

2.  The Importance of an Antimicrobial Stewardship Program.

Authors:  Roula Baroudi; Marquetta Flaugher; Eddie Grace; Danny Zakria
Journal:  Fed Pract       Date:  2015-09

3.  Postoperative plasma concentrations of procalcitonin after different types of surgery.

Authors:  M Meisner; K Tschaikowsky; A Hutzler; C Schick; J Schüttler
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

4.  Integrating Rapid Diagnostics and Antimicrobial Stewardship in Two Community Hospitals Improved Process Measures and Antibiotic Adjustment Time.

Authors:  Ashley M Lockwood; Katherine K Perez; William L Musick; Judy O Ikwuagwu; Engie Attia; Oyejoke O Fasoranti; Patricia L Cernoch; Randall J Olsen; James M Musser
Journal:  Infect Control Hosp Epidemiol       Date:  2016-01-07       Impact factor: 3.254

5.  Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection.

Authors:  Islam M Ghazi; David P Nicolau; Michael D Nailor; Jaber Aslanzadeh; Jack W Ross; Joseph L Kuti
Journal:  Infect Control Hosp Epidemiol       Date:  2016-02-01       Impact factor: 3.254

6.  Use of procalcitonin for antibiotic stewardship in patients with COVID-19: A quality improvement project in a district general hospital.

Authors:  Christina Peters; Kelly Williams; Elena A Un; Louisa Little; Abeer Saad; Katherine Lendrum; Naomi Thompson; Nicholas D Weatherley; Amanda Pegden
Journal:  Clin Med (Lond)       Date:  2020-12-18       Impact factor: 2.659

7.  Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study.

Authors:  Valerie M Vaughn; Tejal N Gandhi; Lindsay A Petty; Payal K Patel; Hallie C Prescott; Anurag N Malani; David Ratz; Elizabeth McLaughlin; Vineet Chopra; Scott A Flanders
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 9.079

8.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.

Authors:  Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

9.  Impact of a Pharmacist-driven Methicillin-resistant Staphylococcus aureus Polymerase Chain Reaction Nasal Swab Protocol on the De-escalation of Empiric Vancomycin in Patients with Pneumonia in a Rural Healthcare Setting.

Authors:  Precious Dadzie; Tyson Dietrich; John Ashurst
Journal:  Cureus       Date:  2019-12-13

10.  Antibiotic misuse in respiratory tract infections in children and adults-a prospective, multicentre study (TAILORED Treatment).

Authors:  Chantal B van Houten; Asi Cohen; Dan Engelhard; John P Hays; Roger Karlsson; Edward Moore; David Fernández; Racheli Kreisberg; Laurence V Collins; Wouter de Waal; Karin M de Winter-de Groot; Tom F W Wolfs; Pieter Meijers; Bart Luijk; Jan Jelrik Oosterheert; Rik Heijligenberg; Sanjay U C Sankatsing; Aik W J Bossink; Andrew Stubbs; Michal Stein; Sharon Reisfeld; Adi Klein; Ronit Rachmilevitch; Jalal Ashkar; Itzhak Braverman; Valery Kartun; Irena Chistyakov; Ellen Bamberger; Isaac Srugo; Majed Odeh; Elad Schiff; Yaniv Dotan; Olga Boico; Roy Navon; Tom Friedman; Liat Etshtein; Meital Paz; Tanya M Gottlieb; Ester Pri-Or; Gali Kronenfeld; Einav Simon; Kfir Oved; Eran Eden; Louis J Bont
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.